« Previous
Next »
Titles
- Medicaid's most costly outpatient drugs2
- A comparison of brand-name drug prices among selected federal programs1
- Assessing user fees under the Prescription Drug User Fee Amendments of 20171
- Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents1
- Brand name drug prices increase more than twice as fast as inflation in 20181
- Brand name prescription drug prices increase four times faster than inflation in 20171
- Changes in the list prices of prescription drugs, 2017-20231
- Competition in prescription drug markets, 2017-20221
- Consumer-driven health plans: a cost and utilization analysis1
- Cost savings1
- Does Medicare Part D protect the elderly from financial risk?1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Filling the Medicaid gap with a public option1
- Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- How does the Trump Administration drug pricing blueprint affect Medicaid?1
- Medicare Part D1
- Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- One percent of drugs with Medicaid reimbursement were not FDA-approved1
- Prescription drug spending by Medicare beneficiaries in institutional and residential settings, 1998-20011